CY1120348T1 - Αμiδια ετεροαρυλιου ως αναστολεις της συσσωματωσης πρωτεϊνων - Google Patents

Αμiδια ετεροαρυλιου ως αναστολεις της συσσωματωσης πρωτεϊνων

Info

Publication number
CY1120348T1
CY1120348T1 CY20181100630T CY181100630T CY1120348T1 CY 1120348 T1 CY1120348 T1 CY 1120348T1 CY 20181100630 T CY20181100630 T CY 20181100630T CY 181100630 T CY181100630 T CY 181100630T CY 1120348 T1 CY1120348 T1 CY 1120348T1
Authority
CY
Cyprus
Prior art keywords
disease
suppliers
terrain
inhibitors
aryl
Prior art date
Application number
CY20181100630T
Other languages
Greek (el)
English (en)
Inventor
Emily M. Stocking
Wolfgang Wrasidlo
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52484559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120348(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of CY1120348T1 publication Critical patent/CY1120348T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20181100630T 2014-01-29 2018-06-15 Αμiδια ετεροαρυλιου ως αναστολεις της συσσωματωσης πρωτεϊνων CY1120348T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461933246P 2014-01-29 2014-01-29
US201462078895P 2014-11-12 2014-11-12
PCT/US2015/013263 WO2015116663A1 (en) 2014-01-29 2015-01-28 Heteroarly amides as inhibitors of protein aggregation

Publications (1)

Publication Number Publication Date
CY1120348T1 true CY1120348T1 (el) 2019-07-10

Family

ID=52484559

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20181100630T CY1120348T1 (el) 2014-01-29 2018-06-15 Αμiδια ετεροαρυλιου ως αναστολεις της συσσωματωσης πρωτεϊνων
CY20201100682T CY1123374T1 (el) 2014-01-29 2020-07-24 Αμιδια ετεροαρυλιου ως αναστολεις της συσσωματωσης πρωτεϊνων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20201100682T CY1123374T1 (el) 2014-01-29 2020-07-24 Αμιδια ετεροαρυλιου ως αναστολεις της συσσωματωσης πρωτεϊνων

Country Status (38)

Country Link
US (3) US9738635B2 (enExample)
EP (2) EP3348556B1 (enExample)
JP (2) JP6619741B2 (enExample)
KR (1) KR102383038B1 (enExample)
CN (2) CN111039939B (enExample)
AP (1) AP2016009347A0 (enExample)
AU (1) AU2015211119B2 (enExample)
BR (2) BR122018001892B1 (enExample)
CA (1) CA2937967C (enExample)
CL (1) CL2016001918A1 (enExample)
CR (1) CR20160394A (enExample)
CY (2) CY1120348T1 (enExample)
DK (2) DK3348556T3 (enExample)
EA (1) EA032374B1 (enExample)
EC (1) ECSP16070327A (enExample)
ES (2) ES2808978T3 (enExample)
HK (1) HK1231470A1 (enExample)
HR (2) HRP20180813T1 (enExample)
HU (2) HUE040274T2 (enExample)
IL (1) IL246987B (enExample)
LT (2) LT3348556T (enExample)
ME (1) ME03800B (enExample)
MX (1) MX2016009896A (enExample)
MY (1) MY187450A (enExample)
NZ (1) NZ722487A (enExample)
PE (1) PE20161393A1 (enExample)
PH (1) PH12016501493A1 (enExample)
PL (2) PL3099684T3 (enExample)
PT (2) PT3348556T (enExample)
RS (2) RS57533B1 (enExample)
SA (1) SA516371579B1 (enExample)
SG (1) SG11201606108RA (enExample)
SI (2) SI3348556T1 (enExample)
SM (2) SMT201800318T1 (enExample)
TR (1) TR201809440T4 (enExample)
UA (1) UA118209C2 (enExample)
WO (1) WO2015116663A1 (enExample)
ZA (1) ZA201605246B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA032374B1 (ru) 2014-01-29 2019-05-31 ЮСиБи БАЙОФАРМА СПРЛ Гетероарильные амиды в качестве ингибиторов агрегации белков
US10975066B2 (en) 2015-07-29 2021-04-13 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
CN106474121B (zh) * 2016-11-25 2017-10-10 刘淑兰 一种治疗慢性盆腔炎的药物
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
RU2019126170A (ru) * 2017-01-26 2021-02-26 Юсб Байофарма Спрл Бисгетероарильные производные в качестве модуляторов агрегации белков
US10889584B2 (en) 2017-01-26 2021-01-12 UCB Biopharma SRL Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation
CN110191885B (zh) * 2017-01-26 2023-05-16 Ucb生物制药私人有限公司 作为蛋白质聚集调节剂的烷氧基双-杂芳基衍生物
JP7283699B2 (ja) * 2017-05-12 2023-05-30 マックス－プランク－ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 黒色腫の治療または予防において使用するためのフェニル－ヘテロ環－フェニル誘導体
EP3664822A4 (en) * 2017-08-04 2021-07-07 Axial Therapeutics, Inc. MICROBIAL INDUCED AMYLOID FORMATION INHIBITORS
CA3079831A1 (en) * 2017-10-31 2019-05-09 Loma Linda University Methods for treating traumatic brain injury
US11707452B2 (en) 2018-08-20 2023-07-25 Arvinas Operations, Inc. Modulators of alpha-synuclein proteolysis and associated methods of use
US20250074902A1 (en) 2021-12-27 2025-03-06 Shanghai Jingxin Biomedical Co., Ltd. Fused bicyclic heteroaryl amide compound as protein aggregation inhibitor
GB202213796D0 (en) * 2022-09-21 2022-11-02 Wista Lab Ltd Tau aggregation inhibitors
JP2025541967A (ja) * 2022-11-02 2025-12-24 エーシー・イミューン・エス・アー Ｔｄｐ－４３タンパク質症の診断のための新規化合物
WO2024184180A1 (en) 2023-03-06 2024-09-12 UCB Biopharma SRL Minzasolmin for use in the treatment of parkinson's disease
WO2024184179A1 (en) 2023-03-06 2024-09-12 UCB Biopharma SRL Minzasolmin for use in the treatment of parkinson's disease
WO2025002040A1 (zh) * 2023-06-25 2025-01-02 上海京新生物医药有限公司 双环杂芳基酰胺化合物的晶型及盐、制备方法和用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1463997A (en) * 1995-12-22 1997-07-17 Acea Pharmaceuticals, Inc. Subtype-selective nmda receptor ligands and the use thereof
WO2004048343A1 (en) * 2002-11-28 2004-06-10 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
CN101385722A (zh) * 2003-02-27 2009-03-18 乔安妮·麦克劳林 预防、治疗和诊断蛋白聚集疾病的方法
TW200528455A (en) * 2003-12-19 2005-09-01 Bristol Myers Squibb Co Azabicyclic heterocycles as cannabinoid receptor modulators
KR20070018824A (ko) * 2003-12-19 2007-02-14 브리스톨-마이어스 스큅 컴퍼니 카나비노이드 수용체 조절제인 아자비사이클릭헤테로사이클
PT1697371E (pt) * 2003-12-19 2007-08-03 Bristol Myers Squibb Co Heterocíclos azabicíclicos como moduladores do receptor de canabinóides
JP4242911B2 (ja) * 2004-08-26 2009-03-25 ファイザー・インク プロテインキナーゼ阻害薬としてのエナンチオピュアなアミノヘテロアリール化合物
CA2580725A1 (en) * 2004-09-20 2006-03-30 4Sc Ag Novel heterocyclic nf-kb inhibitors
SE0403119D0 (sv) * 2004-12-21 2004-12-21 Astrazeneca Ab Therapeutic agents
JP2009505948A (ja) * 2005-07-11 2009-02-12 デブジェン エヌブイ キナーゼ阻害剤としてのアミド誘導体
WO2007016979A2 (en) * 2005-07-29 2007-02-15 4Sc Ag NOVEL HETEROCYCLIC NF-κB INHIBITORS
BRPI0709595A2 (pt) * 2006-03-15 2011-07-19 4Sc Ag inibidores de nf-kapab heterocìclicos
CA2668744C (en) * 2006-11-17 2015-09-15 Queen's University At Kingston Compounds and methods for treating protein folding disorders
US8450481B2 (en) * 2007-06-14 2013-05-28 The Regents Of The University Of California Compounds for inhibiting protein aggregation, and methods for making and using them
US8598356B2 (en) * 2008-11-25 2013-12-03 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
GB0910003D0 (en) * 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
CA2776480A1 (en) * 2009-10-20 2011-04-28 Pfizer Inc. Novel heteroaryl imidazoles and heteroaryl triazoles as gamma-secretase modulators
RU2012129882A (ru) * 2009-12-16 2014-01-27 Нейропор Терапиз, Инк. Соединение
GB201021103D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
WO2013134371A1 (en) 2012-03-06 2013-09-12 Neuropore Therapies, Inc. Methods and compounds to be used in the treatment of neurodegenerative diseases
HK1202452A1 (en) 2012-03-28 2015-10-02 Neuropore Therapies, Inc. Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation
EP2872143B1 (en) * 2012-07-16 2017-12-13 Neuropore Therapies, Inc. Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation
EA032374B1 (ru) 2014-01-29 2019-05-31 ЮСиБи БАЙОФАРМА СПРЛ Гетероарильные амиды в качестве ингибиторов агрегации белков
US10975066B2 (en) 2015-07-29 2021-04-13 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
US10889584B2 (en) 2017-01-26 2021-01-12 UCB Biopharma SRL Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation
RU2019126170A (ru) 2017-01-26 2021-02-26 Юсб Байофарма Спрл Бисгетероарильные производные в качестве модуляторов агрегации белков

Also Published As

Publication number Publication date
LT3348556T (lt) 2020-08-10
ECSP16070327A (es) 2018-05-31
SI3099684T1 (en) 2018-08-31
RS60547B1 (sr) 2020-08-31
AP2016009347A0 (en) 2016-07-31
CA2937967C (en) 2022-07-26
PL3348556T3 (pl) 2020-11-02
IL246987B (en) 2021-12-01
HUE040274T2 (hu) 2019-03-28
KR20160113287A (ko) 2016-09-28
HRP20201107T8 (hr) 2020-12-11
JP2017505779A (ja) 2017-02-23
CR20160394A (es) 2016-11-01
ME03800B (me) 2021-04-20
CN111039939B (zh) 2023-09-19
CN106132960B (zh) 2019-12-17
MY187450A (en) 2021-09-22
IL246987A0 (en) 2016-09-29
JP6619741B2 (ja) 2019-12-11
AU2015211119A1 (en) 2016-08-11
RS57533B1 (sr) 2018-10-31
SMT202000376T1 (it) 2020-09-10
US20160207912A1 (en) 2016-07-21
EP3348556B1 (en) 2020-04-29
PT3099684T (pt) 2018-10-22
JP6783900B2 (ja) 2020-11-11
MX2016009896A (es) 2017-01-11
EA032374B1 (ru) 2019-05-31
SA516371579B1 (ar) 2019-07-16
HUE050964T2 (hu) 2021-01-28
EP3099684B1 (en) 2018-04-04
JP2019163321A (ja) 2019-09-26
NZ722487A (en) 2022-04-29
EP3348556A1 (en) 2018-07-18
AU2015211119B2 (en) 2019-05-30
CL2016001918A1 (es) 2017-01-13
ZA201605246B (en) 2022-05-25
CA2937967A1 (en) 2015-08-06
TR201809440T4 (tr) 2018-07-23
HRP20201107T1 (hr) 2020-10-30
PT3348556T (pt) 2020-07-27
BR112016017344B1 (pt) 2023-05-16
EP3099684B8 (en) 2018-07-04
SG11201606108RA (en) 2016-08-30
US10358443B2 (en) 2019-07-23
US9738635B2 (en) 2017-08-22
ES2675301T3 (es) 2018-07-10
CN111039939A (zh) 2020-04-21
PH12016501493B1 (en) 2017-02-06
BR122018001892B1 (pt) 2023-05-02
UA118209C2 (uk) 2018-12-10
WO2015116663A1 (en) 2015-08-06
US20180093979A1 (en) 2018-04-05
CY1123374T1 (el) 2021-12-31
EA201691529A1 (ru) 2017-01-30
PH12016501493A1 (en) 2017-02-06
BR112016017344A2 (pt) 2017-10-03
PE20161393A1 (es) 2017-01-08
HRP20180813T1 (hr) 2018-07-27
ES2808978T8 (es) 2021-03-22
PL3099684T3 (pl) 2018-09-28
HK1231470A1 (zh) 2017-12-22
DK3348556T3 (da) 2020-08-03
CN106132960A (zh) 2016-11-16
KR102383038B1 (ko) 2022-04-05
SMT201800318T1 (it) 2018-07-17
US20190308965A1 (en) 2019-10-10
EP3099684A1 (en) 2016-12-07
AU2015211119A8 (en) 2016-12-15
LT3099684T (lt) 2018-06-25
US11078196B2 (en) 2021-08-03
ES2808978T3 (es) 2021-03-02
SI3348556T1 (sl) 2020-10-30
DK3099684T3 (en) 2018-07-16
WO2015116663A8 (en) 2016-09-15

Similar Documents

Publication Publication Date Title
CY1123374T1 (el) Αμιδια ετεροαρυλιου ως αναστολεις της συσσωματωσης πρωτεϊνων
CY1120361T1 (el) Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido)
CY1120834T1 (el) Δικυκλικες αζωτουχες ενωσεις ως αγωνιστες μουσκαρινικων υποδοχεων μ1
EA201990221A1 (ru) 1,3-дигидроксифенильные производные, применимые в качестве иммуномодуляторов
EA201691857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
EA201890857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
MX373373B (es) Inhibidores de desmetilasa-1 específica de lisina.
PH12015502028A1 (en) Ido inhibitors
SG10201908028SA (en) Cyclopropylamines as lsd1 inhibitors
MX366875B (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
MX373549B (es) Derivado de pirazol amida.
MX378155B (es) Derivados de 9h-pirrolo-dipiridina.
EP3359521C0 (en) NEW COMPOUNDS FOR THE TREATMENT OF MITOCHONDRIAL DISEASE
MX2019008256A (es) Derivados de bis-heteroarilo biciclicos como moduladores de agregacion de proteinas.
MX2019007053A (es) Derivados de bis-heteroarilo como moduladores de la agregacion de proteinas.
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
EP3449001A4 (en) INHIBITION OF MIR-22-MIRNA BY APT-110
BR112015001096A2 (pt) derivados de di e tri-heteroaril como inibidores de agregação de proteína
MX380290B (es) Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos.
EP3414517A4 (en) HOLOGRAFIC CHARACTERIZATION OF PROTEIN UNITS
BR112016022575A2 (pt) Composições e métodos para o tratamento de doenças neurodegenerativas
MX2019007054A (es) Derivados de alcoxi bis-heteroarilo como moduladores de la agregacion de proteinas.
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
CY1124509T1 (el) Ν,ν-δις-2-μερκαπτοαιθυλο ισοφθαλαμιδιο για τη θεραπεια της νοσου toy parkinson
EA201992022A1 (ru) Терапевтическая рнк